The Valley Desk

ArticleNature communicationsPublished

Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names The Wistar Institute. Affiliation source

Publication record

Type
Article
Venue
Nature communications
Published
Subject terms
Cell Line, Tumor; Animals; Humans; Mice; Melanoma; Sulfonamides; Aniline Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays; Drug Resistance, Neoplasm
PubMed ID
42362544
PubMed Central ID
PMC13421458
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal